产品说明
应用
LY255582 may be used in opioid receptor-mediated cell signaling studies.
包装
5, 25 mg in glass bottle
生化/生理作用
LY255582 inhibits the diet-associated increases in mesolimbic dopamine levels and reduces the consumption of highly-palatable food intake.
LY255582 is a centrally active opioid receptor antagonist (defined as an inverse agonist in 2011 JPET paper) that inhibited weight gain in obese Zucker rats over 30 days. It is more that 5-fold selective for mu opioid receptor compared to kappa opioid receptors and 13-fold selective over delta opioid receptors.
特点和优势
This compound is featured on the Opioid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
基本信息
| 经验(实验)分子式 | C22H35NO2 |
| 分子量 | 345.52 |
| MDL编号 | MFCD00878181 |
| PubChem化学物质编号 | 329825244 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 储存条件 | desiccated |
| 颜色 | white to beige |
| 溶解性 | DMSO: ≥15 mg/mL |
| 创始人 | Eli Lilly |
| 储存温度 | 2-8℃ |
| SMILES string | C[C@H]1CN(CC[C@H](O)C2CCCCC2)CC[C@@]1(C)c3cccc(O)c3 |
| InChI | 1S/C22H35NO2/c1-17-16-23(13-11-21(25)18-7-4-3-5-8-18)14-12-22(17,2)19-9-6-10-20(24)15-19/h6,9-10,15,17-18,21,24-25H,3-5,7-8,11-14,16H2,1-2H3/t17-,21-,22+/m0/s1 |
| InChI key | LVVHEFJXPXAUDD-BULFRSBZSA-N |
安全信息
| 储存分类代码 | 13 - Non Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
